"HER2 negative MBC" trang 1 - tải miễn phí từ tailieunhanh
Distribution of Ki-67 values within HER2 & ER/PgR expression variants of ductal breast cancers as a potential link between IHC features and breast cancer biology

Distribution of Ki-67 values within HER2 & ER/PgR expression variants of ductal breast cancers as a potential link between IHC features and breast cancer biology
13    62    1
Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors

Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors
10    8    1
The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients
10    65    1
Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: A case report and literature review

Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: A case report and literature review
8    59    1
A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer

A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer
9    47    1
Feline mammary basal-like adenocarcinomas: A potential model for human triple-negative breast cancer (TNBC) with basal-like subtype

Feline mammary basal-like adenocarcinomas: A potential model for human triple-negative breast cancer (TNBC) with basal-like subtype
12    42    1
Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status

Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status
11    50    1
Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2- negative metastatic breast cancer: A network meta-analysis

Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2- negative metastatic breast cancer: A network meta-analysis
17    79    0
Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy

Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy
9    90    0
Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2- negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: A propensity score matching study based on SEER database

Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2- negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: A propensity score matching study based on SEER database
11    52    1
SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2- negative advanced stage breast cancer - a multicenter, randomized phase III trial

SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2- negative advanced stage breast cancer - a multicenter, randomized phase III trial
8    54    1
Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016

Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016
13    35    1
A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: A study protocol

A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: A study protocol
5    82    1
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: Efficacy in combination with hormonal therapy

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: Efficacy in combination with hormonal therapy
7    34    1
Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2- negative breast cancer: A randomized pilot trial

Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2- negative breast cancer: A randomized pilot trial
12    43    1
Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: A multicenter real-world study in the northwest of China

Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: A multicenter real-world study in the northwest of China
13    6    1
Pembrolizumab in combination with gemcitabine for patients with HER2‑negative advanced breast cancer: GEICAM/2015–04 (PANGEA‑Breast) study

Pembrolizumab in combination with gemcitabine for patients with HER2‑negative advanced breast cancer: GEICAM/2015–04 (PANGEA‑Breast) study
13    10    1
PIK3CA mutation status, progression and survival in advanced HR+/HER2- breast cancer: A meta-analysis of published clinical trials

PIK3CA mutation status, progression and survival in advanced HR+/HER2- breast cancer: A meta-analysis of published clinical trials
11    1    1
Multiple gene aberrations and breast cancer: Lessons from super-responders

Multiple gene aberrations and breast cancer: Lessons from super-responders
6    30    1